|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/30 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3353212 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16781236.1 |
| Date of filing the European patent application | 2016-09-23 | |
| (97) | Date of publication of the European application | 2018-08-01 |
| (45) | Date of publication and mention of the grant of the patent | 2021-11-03 |
| (46) | Date of publication of the claims translation | 2021-12-27 |
| (86) | Number | PCT/US2016/053525 |
| Date | 2016-09-23 |
| (87) | Number | WO 2017/053856 |
| Date | 2017-03-30 |
| (30) | Number | Date | Country code |
| 201562222605 P | 2015-09-23 | US |
| (72) |
SMITH, Eric , US
HABER, Lauric , US
BABB, Robert , US
CHEN, Gang , US
MACDONALD, Douglas , US
|
| (73) |
Regeneron Pharmaceuticals, Inc. ,
777 Old Saw Mill River Road, Tarrytown, NY 10591-6707,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Optimizuoti anti-CD3 bispecifiniai antikūnai ir jų naudojimas |
| OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-08-20 | 10 | 231.00 EUR |
| 2026-09-23 |